Filing Flows › Vera Therapeutics (VERA) › Guidance & outlook

Vera Therapeutics (VERA) guidance and outlook

Vera Therapeutics' 10-Q filed Nov 5, 2026 makes 20 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 5, 2026

• In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or…
• Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful commercialization of our lead product and development of our product candidates, which we expect will take a number of years.
• We also do not own or operate, and currently have no plans to establish, any manufacturing facilities.
• We rely, and expect to continue to rely, on third parties for the manufacture of our lead product and product candidates.
• Our net losses were $93.7 million and $80.3 million for the three months ended September 30, 2026 and 2025, respectively, and we expect to incur significant and increasing losses for the foreseeable future as we continue to commercialize our lead product and continue to advance our product candidates toward commercialization.
• We expect to continue to incur net operating losses in the near term, and we expect our research and development expenses, selling, general and administrative expenses, and capital expenditures will continue to increase.
• We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we:
• We also expect the cost of our administrative function to increase as we support anticipated growth of our business.
• We will require substantial additional funding to successfully commercialize our lead product, develop our product candidates and support our continuing operations.
• Until such time that we can generate significant revenue from product sales or other sources, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships, or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants.
• We cannot provide assurance that we will ever be profitable or generate positive cash flow from operating activities.
• In addition, we recognize our best estimate of the consideration that we expect to receive when control of the inventory is transferred to our customers, including reserves and accruals for discounts, distribution fees, product returns, chargebacks, rebates, co-pay assistance and other incentives.

Vera Therapeutics' latest quarter

Questions

What does Vera Therapeutics expect?

In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or… Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful commercialization of our lead product and development of our product candidates, wh

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.